Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from XORTX Therapeutics Inc ( (TSE:XRTX) ) is now available.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company specializing in therapies for gout and kidney-related diseases, is advancing multiple programs that target uric acid production and purine metabolism, including late-stage candidates for gout, ADPKD and acute kidney injury, plus a pre-clinical program for diabetic nephropathy. The company announced that shareholders approved all items at its March 24 annual and special meeting, including the election of the full slate of director nominees, appointment of auditors, re-approval of its stock option plan and authorization of a share consolidation, decisions that collectively reinforce its governance framework and provide additional corporate flexibility as it advances its drug development pipeline.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.61 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company developing therapies targeting gout and progressive kidney disease, with a focus on aberrant purine metabolism and xanthine oxidase to reduce uric acid production. Its pipeline includes three clinically advanced programs—XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and organ injury linked to respiratory viral infections—alongside a pre-clinical candidate, XRx-225, for Type 2 diabetic nephropathy.
Average Trading Volume: 5,476
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.46M
For detailed information about XRTX stock, go to TipRanks’ Stock Analysis page.